The role of insulin-like growth factors in the development of prostate cancer

References

• Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019 Sep 27;5(12):1749–1768.
   Web of Science ®Google Scholar
• Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016 Mar 15;138(6):1388–1400.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Goggins WB, Wang HHX, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016 Nov;70(5):862–874.
   PubMed Web of Science ®Google Scholar
• Penson DF, Rossignol M, Sartor AO, et al. Prostate cancer: epidemiology and health-related quality of life. Urology. 2008 Dec;72(6):S3–S11.
   PubMed Web of Science ®Google Scholar
• Brawley OW. Prostate cancer screening: and the pendulum swings. Cancer. 2018 Jul 15;124(14):2890–2892.
   PubMed Web of Science ®Google Scholar
• Carter HB. Prostate-specific antigen (PSA) screening for prostate cancer: revisiting the evidence. JAMA. 2018 May 8;319(18):1866–1868.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014 Oct;15(11):e484–e492.
   PubMed Web of Science ®Google Scholar
• Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008 Feb;15(1):3866–3871.
   PubMed Web of Science ®Google Scholar
• Bell KJL, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015 Oct 1;137(7):1749–1757.
   PubMed Web of Science ®Google Scholar
• Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006 Jul;13(3):158–168.
   PubMedGoogle Scholar
• Guileyardo JM, Johnson WD, Welsh RA, et al. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst. 1980 Aug;65(2):311–316.
   PubMedGoogle Scholar
• Powell IJ, Bock CH, Ruterbusch JJ, et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010 May;183(5):1792–1797.
   Web of Science ®Google Scholar
• Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965–1979 to 1982–1986. J Natl Cancer Inst. 1988 Jul 6;80(9):683–687.
   PubMedGoogle Scholar
• Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013 Jul 17;105(14):1050–1058.
   PubMedGoogle Scholar
• Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982 Jun 15;29(6):611–616.
   PubMed Web of Science ®Google Scholar
• Holly JMP, Zeng L, Perks CM. Epithelial cancers in the post-genomic era: should we reconsider our lifestyle? Cancer Metastasis Rev. 2013 Dec;32(3–4):673–705. .
   PubMed Web of Science ®Google Scholar
• Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, et al. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes Rev. 2018 Jul;19(7):1008–1016.
   PubMed Web of Science ®Google Scholar
• Llaverias G, Danilo C, Wang Y, et al. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol. 2010 Dec;177(6):3180–3191.
   PubMed Web of Science ®Google Scholar
• Holly JMP, Biernacka K, Perks CM. The neglected insulin: IGF-II, a metabolic regulator with implications for diabetes, obesity, and cancer. Cells. 2019 Oct 6;8(10):1207.
   PubMed Web of Science ®Google Scholar
• Holly JMP, Perks CM. Insulin-like growth factor physiology: what we have learned from human studies. Endocrinol Metab Clin North Am. 2012 Jun;41(2):249–263, v.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Malaguarnera R, Vella V, et al. Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev. 2017 Oct 1;38(5):379–431.
   PubMed Web of Science ®Google Scholar
• Morrione A, Valentinis B, Xu S-Q, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3777–3782.
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999 May;19(5):3278–3288.
   PubMed Web of Science ®Google Scholar
• Slaaby R, Schaffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006 Sep 8;281(36):25869–25874.
   PubMed Web of Science ®Google Scholar
• Siddle K. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front Endocrinol (Lausanne). 2012;3:34.
   PubMedGoogle Scholar
• Martin-Kleiner I, Gall Troselj K. Mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis. Cancer Lett. 2010 Mar 1;289(1):11–22.
   PubMed Web of Science ®Google Scholar
• Wang Y, MacDonald RG, Thinakaran G, et al. Insulin-like growth factor-II/cation-independent mannose 6-phosphate receptor in neurodegenerative diseases. Mol Neurobiol. 2017 May;54(4):2636–2658.
   PubMed Web of Science ®Google Scholar
• Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology. 2006;83(3–4):154–160.
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr. 1991;11(1):393–412.
   PubMedGoogle Scholar
• Maile LA, Holly JMP. Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res. 1999 Apr;9(2):85–95.
   PubMed Web of Science ®Google Scholar
• Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014 May;14(5):329–341.
   PubMed Web of Science ®Google Scholar
• Chua MWY, Lin MZ, Martin JL, et al. Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage. J Cell Commun Signal. 2015 Jun;9(2):167–176.
   PubMed Web of Science ®Google Scholar
• Zeng L, Perks CM, Holly JMP. IGFBP-2/PTEN: a critical interaction for tumours and for general physiology? Growth Horm IGF Res. 2015 Jun;25(3):103–107.
   PubMed Web of Science ®Google Scholar
• Zu K, Martin NE, Fiorentino M, et al. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984–1993.
   PubMed Web of Science ®Google Scholar
• Breen KJ, O’Neill A, Murphy L, et al. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. Prostate. 2017 Sep;77(12):1288–1300.
   PubMed Web of Science ®Google Scholar
• Uzoh CC, Holly JM, Biernacka KM, et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011 May 10;104(10):1587–1593.
   PubMed Web of Science ®Google Scholar
• Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170–183.
   PubMedGoogle Scholar
• Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008 Oct 7;149(7):461–471, W83–W88.
   PubMed Web of Science ®Google Scholar
• Travis RC, Appleby PN, Martin RM, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016 Apr 15;76(8):2288–2300.
   PubMed Web of Science ®Google Scholar
• Rowlands M-A, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009 May 15;124(10):2416–2429.
   PubMed Web of Science ®Google Scholar
• Rowlands M-A, Holly JM, Gunnell D, et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res. 2012 Jan 15;72(2):503–515.
   PubMed Web of Science ®Google Scholar
• Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev. 2001;23(2):313–342.
   PubMed Web of Science ®Google Scholar
• Lophatananon A, Stewart-Brown S, Kote-Jarai Z, et al. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br J Cancer. 2017 Aug 22;117(5):734–743.
   PubMed Web of Science ®Google Scholar
• Watts EL, Goldacre R, Key TJ, et al. Hormone-related diseases and prostate cancer: an English national record linkage study. Int J Cancer. 2019 Nov 21. DOI:10.1002/ijc.32808.
   Web of Science ®Google Scholar
• Rohrmann S, Giovannucci E, Smit E, et al. Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination survey. Prostate. 2007 Nov 1;67(15):1693–1698.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia. Clin Chim Acta. 2017 Jun;469:37–41.
   PubMed Web of Science ®Google Scholar
• Correa LL, Balarini Lima GA, Cavallieri SA, et al. Prostatic disorders in acromegalic patients experience of a Brazilian center. Int Braz J Urol. 2013 May-Jun;39(3):393–401.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Chen H-W, Chen M-T, et al. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: a 15-year longitudinal case report. Low Urin Tract Symptoms. 2019 Apr;11(2):O218–O220.
   PubMed Web of Science ®Google Scholar
• Rowlands M-A, Tilling K, Holly JMP, et al. Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. Cancer Causes Control. 2013 Jan;24(1):39–45.
   PubMed Web of Science ®Google Scholar
• Cao Y, Lindstrom S, Schumacher F, et al. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. J Natl Cancer Inst. 2014 Jun;106(5):dju085.
   PubMedGoogle Scholar
• Kim M, Kim JW, Kim JK, et al. Association between serum levels of insulin-like growth factor-1, bioavailable testosterone, and pathologic Gleason score. Cancer Med. 2018 Aug;7(8):4170–4180.
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;Dec;12(12):1429–1437.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Wang L, Horikawa Y, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2005 Jan;26(1):225–231.
   PubMed Web of Science ®Google Scholar
• Hernandez W, Grenade C, Santos ER, et al. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis. 2007 Oct;28(10):2154–2159.
   PubMed Web of Science ®Google Scholar
• Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men’s Health Study. Prostate. 2008 Feb 15;68(3):296–305.
   PubMed Web of Science ®Google Scholar
• Schumacher FR, Cheng I, Freedman ML, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 1;19(15):3089–3101.
   PubMed Web of Science ®Google Scholar
• Qian J, Zhou H, Chen J, et al. Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. PLoS One. 2014;9(2):e85609.
   PubMed Web of Science ®Google Scholar
• Gu F, Schumacher FR, Canzian F, et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2877–2887.
   PubMed Web of Science ®Google Scholar
• Bonilla C, Lewis SJ, Rowlands M-A, et al. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: genetic variants as instruments for circulating levels. Int J Cancer. 2016 Oct 1;139(7):1520–1533.
   PubMed Web of Science ®Google Scholar
• Qie Y, Nian X, Liu X, et al. Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis. Onco Targets Ther. 2016;9:4163–4171.
   PubMed Web of Science ®Google Scholar
• Chang C-F, Pao J-B, Yu C-C, et al. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol. 2013 Jul;20(7):2446–2452.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Narita S, Inoue T, et al. Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. BMC Cancer. 2013 Mar 25;13(1):150.
   PubMedGoogle Scholar
• Biernacka KM, Perks CM, Holly JM. Role of the IGF axis in prostate cancer. Minerva Endocrinol. 2012 Jun;37(2):173–185.
   PubMed Web of Science ®Google Scholar
• Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011 Sep 15;344(1–2):1–24.
   PubMed Web of Science ®Google Scholar
• Seccareccia E, Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res. 2012 Dec;22(6):193–199.
   PubMed Web of Science ®Google Scholar
• Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne). 2014;5:10.
   PubMed Web of Science ®Google Scholar
• Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008 Apr 1;68(7):2479–2488.
   PubMed Web of Science ®Google Scholar
• Sayeed A, Fedele C, Trerotola M, et al. IGF-IR promotes prostate cancer growth by stabilizing α5β1 integrin protein levels. PLoS One. 2013;8(10):e76513.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Kern J, Ofer P, et al. Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget. 2014 May 15;5(9):2723–2735.
   PubMedGoogle Scholar
• Ofer P, Heidegger I, Eder IE, et al. Both IGF1R and INSR knockdown exert antitumorigenic effects in prostate cancer in vitro and in vivo. Mol Endocrinol. 2015 Dec;29(12):1694–1707.
   PubMedGoogle Scholar
• Aleksic T, Gray N, Wu X, et al. Nuclear IGF1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage. Cancer Res. 2018 Jul 1;78(13):3497–3509.
   PubMed Web of Science ®Google Scholar
• Kaplan PJ, Mohan S, Cohen P, et al. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999 May 1;59(9):2203–2209.
   PubMed Web of Science ®Google Scholar
• Xu H, Jiang HW, Ding Q. Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression. Actas Urol Esp. 2015 Apr;39(3):161–168.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang N, Yu B, et al. Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model. Oncogene. 2019 Sep;38(36):6338–6353.
   PubMed Web of Science ®Google Scholar
• Pandini G, Mineo R, Frasca F, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005 Mar 1;65(5):1849–1857.
   PubMed Web of Science ®Google Scholar
• Schayek H, Seti H, Greenberg NM, et al. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol. 2010 Jul 29;323(2):239–245.
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994 Oct 15;54(20):5474–5478.
   PubMed Web of Science ®Google Scholar
• Itkonen HM, Mills IG. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One. 2013;8(5):e65016.
   PubMed Web of Science ®Google Scholar
• Plymate SR, Haugk K, Coleman I, et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res. 2007 Nov 1;13(21):6429–6439.
   PubMed Web of Science ®Google Scholar
• Nickerson T, Chang F, Lorimer D, et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001 Aug 15;61(16):6276–6280.
   PubMed Web of Science ®Google Scholar
• Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 2003 Jul 1;63(13):3575–3584.
   PubMed Web of Science ®Google Scholar
• Miyake H, Nelson C, Rennie PS, et al. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3ʹ-kinase pathway. Endocrinology. 2000 Jun;141(6):2257–2265.
   PubMed Web of Science ®Google Scholar
• Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, et al. Antitumor activity of the IGF-1/IGF-2–neutralizing antibody xentuzumab (BI 836845) in combination with enzalutamide in prostate cancer models. Mol Cancer Ther. 2020 Feb 13;19(4):1059–1069.
   PubMed Web of Science ®Google Scholar
• Yu EY, Li H, Higano CS, et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2015 May 10;33(14):1601–1608.
   PubMed Web of Science ®Google Scholar
• Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene. 2012 May 31;31(22):2703–2714.
   PubMed Web of Science ®Google Scholar
• Werner H, Meisel-Sharon S, Bruchim I. Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway. Mol Cancer. 2018 Feb 19;17(1):28.
   PubMedGoogle Scholar
• Schayek H, Haugk K, Sun S, et al. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res. 2009 Mar 1;15(5):1558–1565.
   PubMed Web of Science ®Google Scholar
• Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016 Jan 28;35(4):403–414.
   PubMed Web of Science ®Google Scholar
• Song C, Chen H. Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis. Cancer Cell Int. 2018;18(1):177.
   PubMedGoogle Scholar
• Mancarella C, Casanova-Salas I, Calatrava A, et al. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget. 2015 Jun 30;6(18):16611–16622.
   PubMedGoogle Scholar
• Meisel Sharon S, Pozniak Y, Geiger T, et al. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1. Oncotarget. 2016 Aug 9;7(32):51375–51392.
   PubMedGoogle Scholar
• Damaschke NA, Yang B, Bhusari S, et al. Loss of Igf2 gene imprinting in murine prostate promotes widespread neoplastic growth. Cancer Res. 2017 Oct 1;77(19):5236–5247. .
   PubMed Web of Science ®Google Scholar
• Yang B, Wagner J, Damaschke N, et al. A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS One. 2014;9(2):e88052.
   PubMed Web of Science ®Google Scholar
• Dobosy JR, Fu VX, Desotelle JA, et al. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. Prostate. 2008 Aug 1;68(11):1187–1195.
   PubMed Web of Science ®Google Scholar
• Chen Q, Sun T, Wang F, et al. Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer. Urology. 2019 Feb;124:310 e1–310 e8.
   Web of Science ®Google Scholar
• Vidal SJ, Rodriguez-Bravo V, Quinn SA, et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 2015 Feb 9;27(2):223–239.
   PubMed Web of Science ®Google Scholar
• Lubik AA, Gunter JH, Hollier BG, et al. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2013 Apr;20(2):173–186.
   PubMed Web of Science ®Google Scholar
• Bacci L, Aiello A, Ripoli C, et al. H19-dependent transcriptional regulation of β3 and β4 integrins upon estrogen and hypoxia favors metastatic potential in prostate cancer. Int J Mol Sci. 2019 Aug 17;20(16):4012.
   PubMed Web of Science ®Google Scholar
• Bauderlique-Le Roy H, Vennin C, Brocqueville G, et al. Enrichment of human stem-like prostate cells with s-SHIP promoter activity uncovers a role in stemness for the long noncoding RNA H19. Stem Cells Dev. 2015 May 15;24(10):1252–1262.
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen Q, Liu X, et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. Febs J. 2014 Aug;281(16):3766–3775.
   PubMed Web of Science ®Google Scholar
• Yang Z-G, Ma X-D, He Z-H, et al. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5. Int Braz J Urol. 2017 Nov-Dec;43(6):1060–1067.
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Wade SW, Reich A, et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018 Jan 6;18(1):44.
   PubMedGoogle Scholar
• Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am. 2012 Jun;41(2):323–333, vi.
   PubMed Web of Science ®Google Scholar
• Yakar S, Werner H, Rosen CJ. Insulin-like growth factors: actions on the skeleton. J Mol Endocrinol. 2018 Jul;61(1):T115–T137.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005 Jan;5(1):21–28.
   PubMed Web of Science ®Google Scholar
• Rieunier G, Wu X, Macaulay VM, et al. Bad to the bone: the role of the insulin-like growth factor axis in osseous metastasis. Clin Cancer Res. 2019 Jun 15;25(12):3479–3485.
   PubMed Web of Science ®Google Scholar
• Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 2004 Sep 1;64(17):6252–6258.
   PubMed Web of Science ®Google Scholar
• Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res. 2010 Jan 1;16(1):121–129.
   PubMed Web of Science ®Google Scholar
• Nordstrand A, Lundholm M, Larsson A, et al. Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone. Cancer Microenviron. 2013 Dec;6(3):231–240.
   PubMedGoogle Scholar
• Nordstrand A, Bergstrom SH, Thysell E, et al. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone. Clin Exp Metastasis. 2017 Apr;34(3–4):261–271.
   PubMed Web of Science ®Google Scholar
• Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019 Aug 14;8(8):895. .
   PubMed Web of Science ®Google Scholar
• Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003 Aug 15;63(16):5073–5083.
   PubMed Web of Science ®Google Scholar
• Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005 Apr 15;11(8):3065–3074.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhu Z, Xiao X, et al. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther. 2006 Jan;5(1):114–120.
   PubMed Web of Science ®Google Scholar
• Fahrenholtz CD, Beltran PJ, Burnstein KL. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol Cancer Ther. 2013 Apr;12(4):394–404.
   PubMed Web of Science ®Google Scholar
• Galet C, Gray A, Said JW, et al. Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. Int J Mol Sci. 2013 Jul 3;14(7):13782–13795.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009 May 1;15(9):3058–3067.
   PubMed Web of Science ®Google Scholar
• Isebaert SF, Swinnen JV, McBride WH, et al. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):239–247.
   PubMed Web of Science ®Google Scholar
• Chitnis MM, Lodhia KA, Aleksic T, et al. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene. 2014 Nov 6;33(45):5262–5273.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia. Aging Male. 2018 Jun;21(2):138–144.
   PubMed Web of Science ®Google Scholar
• Bhusari S, Yang B, Kueck J, et al. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate. 2011 Nov;71(15):1621–1630.
   PubMed Web of Science ®Google Scholar
• Fu VX, Dobosy JR, Desotelle JA, et al. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res. 2008 Aug 15;68(16):6797–6802.
   PubMed Web of Science ®Google Scholar
• Tennant MK, Thrasher JB, Twomey PA, et al. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab. 1996 Oct;81(10):3774–3782.
   PubMed Web of Science ®Google Scholar
• Kuffer S, Gutting T, Belharazem D, et al. Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation. Mol Oncol. 2018 Feb;12(2):256–266.
   PubMed Web of Science ®Google Scholar
• Schagdarsurengin U, Lammert A, Schunk N, et al. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4. Cell Commun Signal. 2017 Oct 10;15(1):40.
   PubMedGoogle Scholar
• Belharazem D, Kirchner M, Geissler F, et al. Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer. Endocr Connect. 2012 Nov 1;1(2):87–94.
   PubMed Web of Science ®Google Scholar
• Ribarska T, Goering W, Droop J, et al. Deregulation of an imprinted gene network in prostate cancer. Epigenetics. 2014 May;9(5):704–717.
   PubMed Web of Science ®Google Scholar
• Korzeniewski N, Tosev G, Pahernik S, et al. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol. 2015 Jan;33(1):16e17–16e22.
   Web of Science ®Google Scholar
• Fischer D, Wahlfors T, Mattila H, et al. MiRNA profiles in lymphoblastoid cell lines of finnish prostate cancer families. PLoS One. 2015;10(5):e0127427.
   PubMed Web of Science ®Google Scholar
• Howard EW, Leung SCL, Yuen HF, et al. Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clin Exp Metastasis. 2008;25(5):497–508.
   PubMed Web of Science ®Google Scholar
• Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, et al. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer. 2010 Jun 30;10(1):341.
   PubMedGoogle Scholar
• Chromecki TF, Cha EK, Pummer K, et al. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU Int. 2012 Jul;110(1):63–68.
   PubMed Web of Science ®Google Scholar
• Szarvas T, Tschirdewahn S, Niedworok C, et al. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer. 2014 Oct 1;135(7):1596–1604.
   PubMed Web of Science ®Google Scholar
• Turney BW, Turner GDH, Brewster SF, et al. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int. 2011 May;107(9):1488–1499.
   PubMed Web of Science ®Google Scholar
• Aleksic T, Verrill C, Bryant RJ, et al. IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. Br J Cancer. 2017 Nov 21;117(11):1600–1606.
   PubMed Web of Science ®Google Scholar
• Ahearn TU, Peisch S, Pettersson A, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 Dec 31;39(12):1431–1437.
   PubMed Web of Science ®Google Scholar
• Mancarella C, Casanova-Salas I, Calatrava A, et al. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status. BMC Cancer. 2017 May 25;17(1):367.
   PubMedGoogle Scholar
• Hussain M, Rathkopf D, Liu G, et al. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015 Sep;51(13):1714–1724.
   PubMed Web of Science ®Google Scholar
• Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer. 2010 Jul 27;103(3):332–339.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Piulats JM, Pandha HS, et al. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Apr 1;20(7):1925–1934.
   PubMed Web of Science ®Google Scholar
• Dean JP, Sprenger CC, Wan J, et al. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013 May;98(5):E820–E828.
   PubMed Web of Science ®Google Scholar
• Chi KN, Gleave ME, Fazli L, et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res. 2012 Jun 15;18(12):3407–3413.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Massoner P, Sampson N, et al. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Lett. 2015 Oct 28;367(2):113–121.
   PubMed Web of Science ®Google Scholar
• McHugh DJ, Chudow J, DeNunzio M, et al. A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2020 Jan 11. DOI:10.1016/j.clgc.2019.10.013.
   PubMedGoogle Scholar
• Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res. 2012 Jan 1;18(1):40–50.
   PubMed Web of Science ®Google Scholar
• Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol. 2013 Apr;228(4):675–679.
   PubMed Web of Science ®Google Scholar
• Holly JMP, Biernacka K, Perks CM. Systemic metabolism, its regulators, and cancer: past mistakes and future potential. Front Endocrinol (Lausanne). 2019;10:65.
   PubMed Web of Science ®Google Scholar